MY-T study: Symptom-based titration decisions when using testosterone nasal gel, Natesto^®

Area of Science:

• Endocrinology
• Andrology
• Pharmacology

Background:

• Hypogonadism in adult males requires testosterone therapy (TTh).
• Natesto® (testosterone nasal gel, TNG) is indicated for adult male hypogonadism.
• Physician assessment of patient symptoms is crucial for TTh titration.

Purpose of the Study:

• To evaluate the efficacy of TNG in treating hypogonadal males.
• To assess the impact of physician-guided titration on TTh outcomes.
• To identify symptoms predictive of treatment response.

Main Methods:

• Hypogonadal males (TThE or TThN) received 22 mg TNG daily for 90 days.
• Dose titration to 33 mg daily was based on physician assessment of symptoms at day 90.
• Total testosterone (TT) and quantitative Androgen Deficiency in the Aging Male (qADAM) scores were monitored.

Main Results:

• 77.0% of patients achieved normal TT levels by study endpoint.
• Mean qADAM scores increased from baseline, indicating symptom improvement.
• 37% of patients required dose up-titration, but qADAM scores did not significantly change at the higher dose.

Conclusions:

• TNG facilitates testosterone level normalization when titration is guided by symptom assessment.
• Sexual function and energy-related symptoms are key indicators for TNG titration.
• Physician-led symptom evaluation ensures effective TTh management for hypogonadal males.